

**REMARKS**


**Claim status.** Claims 17 to 25, 39 to 42, and 62 to 64 are now in the case. Claims 17, 19, 20, 24, and 39 to 42 are currently amended. Claims 65 and 66 are canceled hereby.

Claims 19, 20 and 24 are amended to address informalities as mentioned in the office action mailed June 10, 2004. Claim 66 is canceled as duplicative of Claim 24, as mentioned in the office action. Claim 17 is amended and Claim 65 is canceled based on the Examiner's conclusion that they contain unelected subject matter. The Applicants reserve the right to file one or more divisional applications on the subject matter removed by these amendments.

**Rejection under Section 112, first paragraph.** In the interest of compact prosecution, the Applicants have amended the claims to recite treatment of bone loss rather than treatment of conditions resulting in bone loss as suggested by the Examiner. The Applicants' belief is that claims are now directed to the subject matter that the Examiner deemed enabled.

**Conclusion.** In light of the foregoing amendments and remarks, the Applicants respectfully request entry of all amendments, withdrawal of all objections and rejections, and allowance of all claims.

Respectfully submitted,



Timothy J. Gaul  
Attorney for Applicants  
Registration No.: 33,111  
Phone: (805) 447-2688  
Date: September 10, 2004

Please send all future correspondence to:  
US Patent Operations/ TJG  
Dept. 4300, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799